Phil Alper

Phil Alper

Auto-generated profile, based on publicly available information

Phil Alper

Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Dr., San Diego, CA 92121, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017
Verified
Open access
DTDavid C. Tully
David C. Tully
PRPaul V. Rucker
Paul V. Rucker
DCDonatella Chianelli
Donatella Chianelli
JWJennifer Williams
Jennifer Williams
AVAgnès Vidal
Agnès Vidal
BLBryan Laffitte
Bryan Laffitte
The farnesoid X receptor (FXR) is a nuclear receptor that acts as a master regulator of bile acid metabolism and signaling. Activation of FXR inhibits bile acid synthesis and increases bile acid conjugation, transport, and excretion, thereby protecting the liver from the harmful effects of bile accumulation, leading to considerable interest in FXR as a therapeutic target for the treatment of cholestasis and nonalcoholic steatohepatitis. We identified a novel series of highly potent non-bile acid FXR agonists that introduce a bicyclic nortropine-substituted benzothiazole carboxylic acid moiety onto a trisubstituted isoxazole scaffold. Herein, we report the discovery of 1 (tropifexor, LJN452), a novel and highly potent agonist of FXR. Potent in vivo activity was demonstrated in rodent PD models by measuring the induction of FXR target genes in various tissues. Tropifexor has advanced into phase 2 human clinical trials in patients with NASH and PBC.

30 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKThomas Knoepfel
Thomas Knoepfel
PNPierre Nimsgern
Pierre Nimsgern
SJSébastien Jacquier
Sébastien Jacquier
MBMarjorie Bourrel
Marjorie Bourrel
EVEric Vangrevelinghe
Eric Vangrevelinghe
CBClaudia Betschart
Claudia Betschart

1 October 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PAPhil B. Alper
Phil B. Alper
TMThomas H. Marsilje
Thomas H. Marsilje
DMDaniel Mutnick
Daniel Mutnick
WLWenshuo Lu
Wenshuo Lu
ACArnab Chatterjee
Arnab Chatterjee
STShin-Shay Tian
Shin-Shay Tian

8 February 2003 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
PAPhil B. Alper
Phil B. Alper
KNKhanhLinh T. Nguyen
KhanhLinh T. Nguyen

1 March 2006 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PAPhillip B. Alper
Phillip B. Alper
HLHong Liu
Hong Liu
ACArnab K. Chatterjee
Arnab K. Chatterjee
KNKhanhLinh T. Nguyen
KhanhLinh T. Nguyen
DTDavid C. Tully
David C. Tully
DKDonald S. Karanewsky
Donald S. Karanewsky

31 July 2023 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
PAPhil Alper
Phil Alper
CBClaudia Betschart
Claudia Betschart
CACédric André
Cédric André
TBThomas Boulay
Thomas Boulay
DCDai Cheng
Dai Cheng
PMPierre-Yves Michellys
Pierre-Yves Michellys